Welcome to our dedicated page for Royalty Pharma plc news (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma plc stock.
Royalty Pharma plc (Nasdaq: RPRX) is the leading acquirer of revenue-producing intellectual property, primarily focusing on royalty interests in marketed and late-stage biopharmaceutical products. Established in 1996, the company has built a robust portfolio with over $13 billion in assets and has invested nearly $5.8 billion to date. Royalty Pharma excels in acquiring and managing diverse royalty interests across various therapeutic areas, mitigating the common risks associated with biopharmaceutical investments.
Royalty Pharma's portfolio includes royalties on more than 35 commercial products, such as AbbVie and Johnson & Johnson's Imbruvica for blood cancers, Biogen's Tysabri for multiple sclerosis, and Vertex's cystic fibrosis drugs. The company also holds interests in 14 development-stage products, demonstrating its commitment to funding innovation in the biopharmaceutical sector.
Recent achievements include a $525 million acquisition of royalties and milestones on frexalimab, a promising therapy developed by Sanofi for multiple sclerosis and other immune-mediated diseases. This transaction enhances Royalty Pharma's development-stage portfolio, reinforcing its potential for long-term growth.
Financially, Royalty Pharma reported first-quarter 2024 results reflecting strong royalty receipts growth, driven by key therapies like Trelegy and Vertex’s cystic fibrosis franchise. The company maintains a solid liquidity position with $843 million in cash and cash equivalents and a total debt of $6.3 billion.
Royalty Pharma's strategic partnerships span a broad spectrum of innovators, from academic institutions and research hospitals to leading global pharmaceutical companies. This extensive collaboration network underscores the company's pivotal role in advancing medical research and providing essential funding for late-stage clinical trials and new product launches.
For more information, visit www.royaltypharma.com.
Royalty Pharma (RPRX) has declared a $0.17 dividend per class A share for Q1 2021, marking a 13% increase over the previous quarter. This reflects the company's commitment to returning value to shareholders. The dividend will be paid on March 15, 2021, to shareholders on record as of February 19, 2021. As the largest buyer of biopharmaceutical royalties, Royalty Pharma continues to fund innovation in the sector, collaborating with various biotech and pharmaceutical companies.
Royalty Pharma (Nasdaq: RPRX) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 10:50 a.m. EST. The presentation is open to investors, analysts, and the public, with a live webcast available at Royalty Pharma Events. A replay will be archived for at least 30 days. Founded in 1996, Royalty Pharma is a leading buyer of biopharmaceutical royalties and funds innovation across the industry, with a portfolio of royalties on over 45 commercial products.
Royalty Pharma plc (Nasdaq: RPRX) announced charitable donations of $7,660,000 to support COVID-19 research at prestigious institutions, including The Rockefeller University and Mount Sinai Health System. This contribution comprises $4,880,000 from Royalty Pharma and $2,880,000 from Pablo and Almudena Legorreta. The funding aims to advance antibody therapy research and studies on seroprevalence and vaccine responses, particularly for minority communities. The initiative underscores Royalty Pharma's commitment to combating the COVID-19 pandemic through scientific innovation.
Royalty Pharma plc (Nasdaq: RPRX) expands its leadership team, promoting Jim Reddoch to Chief Scientific Officer and Marshall Urist to Executive Vice President, Co-Head of Research & Investments. Sandy Balkin joins as Senior Vice President, Strategy and Analytics. This strategic restructuring aims to enhance the company's capabilities in evaluating and executing new investment opportunities. The leadership change reflects a commitment to leveraging data analytics for innovation in the biopharmaceutical sector, amidst growing transaction activities.
Royalty Pharma (RPRX) and Athyrium Capital Management have announced a transaction involving $325 million in funding for BioCryst Pharmaceuticals (BCRX). This includes an upfront payment of $125 million from Royalty Pharma to support the launch of ORLADEYO™ in hereditary angioedema and the development of BCX9930, an oral Factor D inhibitor. BioCryst will also receive a $200 million credit facility from Athyrium, ensuring financial liquidity while aiming for growth in disease treatment areas. This strategic partnership is anticipated to enhance BioCryst's market position significantly.
Royalty Pharma reported strong Q3 2020 results with a 17% increase in net cash from operations, totaling $509 million. Adjusted Cash Receipts rose 12% to $472 million, driven by the CF franchise and Imbruvica. The company announced $2.3 billion in new acquisitions this year and adjusted full-year guidance to $1,780-$1,800 million. Significant investments include a $575 million acquisition of CF royalties. The balance sheet improved with a $6 billion bond offering, extending debt maturity to 12.5 years. Positive clinical data for Trodelvy was also highlighted.
Royalty Pharma (RPRX) has agreed to acquire the residual royalty interest in Vertex Pharmaceuticals' cystic fibrosis treatments from the Cystic Fibrosis Foundation for $575 million, with a potential additional $75 million in milestone payments. This transaction allows Royalty Pharma to retain all royalties above the previous $5.8 billion revenue threshold. The Vertex CF franchise generated over $4.0 billion in net revenues in 2019. This acquisition is expected to bolster Royalty Pharma's Adjusted Cash Receipts and Cash Flow growth, reflecting their commitment to funding biopharmaceutical innovation.
Royalty Pharma announced the closing of a secondary offering of 17,343,037 Class A ordinary shares at $42.00 per share. Proceeds from the sale will not benefit the company, as the shares were sold by existing shareholders. The SEC declared the registration statement effective on October 15, 2020. The offering was managed by major financial institutions including J.P. Morgan and Morgan Stanley. Royalty Pharma is a prominent buyer of biopharmaceutical royalties and funds innovation in the sector, holding royalties on over 45 commercial products.
Royalty Pharma (Nasdaq: RPRX) plans to report its third quarter 2020 financial results on November 11, 2020, prior to the U.S. market opening. A conference call will be held at 8:00 a.m. ET that day, accessible via phone at (833) 519-1253 or (914) 800-3826 for international callers, using passcode 8067315. The live webcast will be available on the company’s Investors page. Royalty Pharma is recognized as the largest buyer of biopharmaceutical royalties and a key innovator in the biopharmaceutical sector.
Royalty Pharma plc (Nasdaq: RPRX) has priced a secondary offering of 17,343,037 Class A ordinary shares at $42.00 per share, with selling shareholders and an option for underwriters to purchase an additional 2,601,455 shares. The company will not receive any proceeds from this sale. The offering is expected to close on October 20, 2020. Major banks such as J.P. Morgan and Morgan Stanley are leading the underwriting process. This offering comes as part of Royalty Pharma's strategy, positioning the company within the biopharmaceutical sector, focusing on royalties and innovation funding.
FAQ
What is the current stock price of Royalty Pharma plc (RPRX)?
What is the market cap of Royalty Pharma plc (RPRX)?
What does Royalty Pharma do?
What are some key products in Royalty Pharma’s portfolio?
How does Royalty Pharma fund innovation?
What is the company's financial position?
What recent acquisitions has Royalty Pharma made?
How does Royalty Pharma mitigate risks?
Who are Royalty Pharma’s partners?
What are Royalty Pharma’s recent financial results?
What is Royalty Pharma’s strategy?
Where can I find more information about Royalty Pharma?
